US Pharma MarketingCurium to acquire Lantheus in all-cash deal worth up to $8bn
CapVest Partners-backed Curium has agreed to acquire rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn.
CapVest Partners-backed Curium has agreed to acquire rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn.
Source: Pharmaceutical Technology